Targeted Sequencing-Based Re-Evaluation of Candidate Immunogenetic Variants for Biologic Treatment Response and Difficult-to-Treat Rheumatoid Arthritis
Authors:
- Alena I. ZagrebnevaAZAlena I. Zagrebneva
- Elena N. SimonovaESElena N. Simonova
- Yuliya A. GavrikovaYGYuliya A. Gavrikova
- Vladislav V. DolgovVDVladislav V. Dolgov
- Anastasiia A. BuianovaAnastasiia A. Buianova
- Ekaterina D. GlumovaEGEkaterina D. Glumova
- Maria I. TubalovaMTMaria I. Tubalova
- Galina S. KoksharovaGKGalina S. Koksharova
- Artem R. NurislamovANArtem R. Nurislamov
- Vadim I. MazurovVMVadim I. Mazurov
Open Access
- 1 October 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (19) , 8800
Abstract
Genetic determinants of response to biologic disease-modifying antirheumatic drugs (bDMARDs) in rheumatoid arthritis (RA) remain insufficiently characterized. We developed a targeted sequencing panel of candidate immunogenetic variants identified through a literature review and evaluated associations with response to TNF-α inhibitors, response to IL-6 inhibitors, and difficult-to-treat RA (D2TRA). Whole-blood DNA was sequenced using custom hybridization capture on a DNBSEQ-G400 platform (2 × 150 bp). Reads were aligned to hg38 using BWA-MEM, and variants were called with GATK HaplotypeCaller. After quality control, the D2TRA analysis included 154 patients (59 D2TRA and 95 non-D2TRA); drug-response analyses included 66 anti-TNF patients (26 responders, 40 non-responders) and 69 anti-IL-6 patients (29 responders, 40 non-responders). Treatment-response associations were assessed using unadjusted allelic chi-square tests with multiple-testing correction; D2TRA was analyzed using logistic regression adjusted for age, sex, and body mass index. For IL-6 inhibitor response, rs11656130/MAP2K6 (p = 0.0163; FDR = 0.3704) and rs4910008/GALNT18 (p = 0.0212; FDR = 0.3704) were identified, while rs7767069/LINC02549 was associated with TNF-α inhibitor response (p = 0.0171; FDR = 0.5968). For D2TRA, rs1813443 in CNTN5 (OR = 1.85, p = 0.017) and rs12081765, an intergenic variant near LMX1A/RXRG (OR = 0.59, p = 0.028), were nominally associated; neither association remained significant after multiple-testing correction. With the current sample sizes, the study could detect only large genetic effects, and was underpowered for these after Bonferroni correction (α = 0.00143). The findings highlight the limited reproducibility of candidate pharmacogenetic markers in RA and provide a targeted panel and analytical framework for larger replication studies.Keywords
Funding Information
- Ministry of Health of the Russian Federation (1025101700003-6)
This publication has 39 references indexed in Scilit:
- The impact of gene polymorphisms on the response of methotrexate-based treatmentsEuropean Journal of Clinical Pharmacology, 2026
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 updateAnnals of the Rheumatic Diseases, 2026
- POS0713 PERIPHERAL BLOOD MONONUCLEAR CELL TRANSCRIPTOMICS AND PLASMA METABOLOMICS REVEAL THE ROLE OF NEUROINFLAMMATION AND NEUROPLASTICITY IN THE BACKGROUND OF DIFFICULT-TO-TREAT RHEUMATOID ARTHRITISAnnals of the Rheumatic Diseases, 2025
- Rheumatoid arthritis: pathogenesis and therapeutic advancesMedcomm, 2024
- Retinoid X Receptor: Cellular and Biochemical Roles of Nuclear Receptor with a Focus on Neuropathological InvolvementMolecular Neurobiology, 2022
- Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trialThe Lancet, 2021
- Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritisThe Pharmacogenomics Journal, 2018
- Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritisPharmacological Research, 2016
- Pain genetics: past, present and futureTrends in Genetics, 2012
- Quantitative heritability of anti–citrullinated protein antibody–positive and anti–citrullinated protein antibody–negative rheumatoid arthritisArthritis & Rheumatism, 2009